PF-06842874

PF‑06842874 is an investigational small molecule that acts as a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6). It was developed by Pfizer for the treatment of pulmonary arterial hypertension and received orphan drug designation in the United States for this indication. The drug reached Phase 1 clinical trials but development was discontinued after these early studies. Its mechanism involves targeting cell cycle regulation pathways via CDK4/6 inhibition[2][3][5][9].

Other names

3-acetyl-1-cyclopentyl-7-(((3s,4r)-3-hydroxyoxan-4-yl)amino)-4-methyl-1,6-naphthyridin-2(1h)-one3-Acetyl-1-cyclopentyl-7-{[(3S,4R)-3-hydroxyoxan-4-yl]amino}-4-methyl-1,6-naphthyridin-2(1H)-one